BACKGROUND AND OBJECTIVES:Velpatasvir (VEL; GS-5816) is a potent, pangenotypic hepatitis C virus (HCV), non-structural protein 5A inhibitor in clinical development for the treatment of chronic HCV infection. In vitro studies indicate that VEL may inhibit several drug transporters and be a substrate for enzyme/drug transport systems in vivo. The purpose of this study was to evaluate the potential of VEL as a perpetrator or victim of metabolic- and transporter-based drug-drug interactions using complementary probe drugs. METHODS: This Phase 1 study was a randomized, cross-over, open-label, single- and multiple-dose, five-cohort study. Serial blood samples were collected following oral administration of reference and test treatments. The primary pharmacokinetic parameters of each analyte were compared when administered alone or in combination. The 90% confidence intervals (CI) for the ratio of the geometric least-squares means of the test and reference treatments was calculated for each analyte and parameter of interest. RESULTS: This study demonstrated that VEL is a weak (P-gp, OATP) to moderate (breast cancer resistance protein) transport inhibitor. As a victim of interactions, VEL is moderately affected by potent inhibitors and to a greater extent, potent inducers of enzyme/drug transporter systems. CONCLUSIONS: The impact of specific transporters and overall contribution of drug transport vs. metabolizing enzymes on the disposition of VEL was characterized through the use of complementary probes, despite the lack of phenotypic specificity, and informs a broad range of drug-drug interaction recommendations.
RCT Entities:
BACKGROUND AND OBJECTIVES:Velpatasvir (VEL; GS-5816) is a potent, pangenotypic hepatitis C virus (HCV), non-structural protein 5A inhibitor in clinical development for the treatment of chronic HCV infection. In vitro studies indicate that VEL may inhibit several drug transporters and be a substrate for enzyme/drug transport systems in vivo. The purpose of this study was to evaluate the potential of VEL as a perpetrator or victim of metabolic- and transporter-based drug-drug interactions using complementary probe drugs. METHODS: This Phase 1 study was a randomized, cross-over, open-label, single- and multiple-dose, five-cohort study. Serial blood samples were collected following oral administration of reference and test treatments. The primary pharmacokinetic parameters of each analyte were compared when administered alone or in combination. The 90% confidence intervals (CI) for the ratio of the geometric least-squares means of the test and reference treatments was calculated for each analyte and parameter of interest. RESULTS: This study demonstrated that VEL is a weak (P-gp, OATP) to moderate (breast cancer resistance protein) transport inhibitor. As a victim of interactions, VEL is moderately affected by potent inhibitors and to a greater extent, potent inducers of enzyme/drug transporter systems. CONCLUSIONS: The impact of specific transporters and overall contribution of drug transport vs. metabolizing enzymes on the disposition of VEL was characterized through the use of complementary probes, despite the lack of phenotypic specificity, and informs a broad range of drug-drug interaction recommendations.
Authors: K Maeda; Y Ikeda; T Fujita; K Yoshida; Y Azuma; Y Haruyama; N Yamane; Y Kumagai; Y Sugiyama Journal: Clin Pharmacol Ther Date: 2011-08-10 Impact factor: 6.875
Authors: Kathleen M Giacomini; Shiew-Mei Huang; Donald J Tweedie; Leslie Z Benet; Kim L R Brouwer; Xiaoyan Chu; Amber Dahlin; Raymond Evers; Volker Fischer; Kathleen M Hillgren; Keith A Hoffmaster; Toshihisa Ishikawa; Dietrich Keppler; Richard B Kim; Caroline A Lee; Mikko Niemi; Joseph W Polli; Yuichi Sugiyama; Peter W Swaan; Joseph A Ware; Stephen H Wright; Sook Wah Yee; Maciej J Zamek-Gliszczynski; Lei Zhang Journal: Nat Rev Drug Discov Date: 2010-03 Impact factor: 84.694
Authors: Markus Cornberg; Homie A Razavi; Alfredo Alberti; Enos Bernasconi; Maria Buti; Curtis Cooper; Olav Dalgard; John F Dillion; Robert Flisiak; Xavier Forns; Sona Frankova; Adrian Goldis; Ioannis Goulis; Waldemar Halota; Bela Hunyady; Martin Lagging; Angela Largen; Michael Makara; Spilios Manolakopoulos; Patrick Marcellin; Rui T Marinho; Stanislas Pol; Thierry Poynard; Massimo Puoti; Olga Sagalova; Scott Sibbel; Krzysztof Simon; Carolyn Wallace; Kendra Young; Cihan Yurdaydin; Eli Zuckerman; Francesco Negro; Stefan Zeuzem Journal: Liver Int Date: 2011-07 Impact factor: 5.828
Authors: M J Gale; M J Korth; N M Tang; S L Tan; D A Hopkins; T E Dever; S J Polyak; D R Gretch; M G Katze Journal: Virology Date: 1997-04-14 Impact factor: 3.616
Authors: Erik Mogalian; Diana M Brainard; Anu Osinusi; Lisa Moorehead; Bernard Murray; Kah Hiing John Ling; Robert Perry; Craig Curtis; Eric Lawitz; Kenneth Lasseter; Thomas Marbury; Anita Mathias Journal: Clin Pharmacokinet Date: 2018-11 Impact factor: 6.447
Authors: Roberto Minutolo; Alessio Aghemo; Antonio Chirianni; Fabrizio Fabrizi; Loreto Gesualdo; Edoardo G Giannini; Paolo Maggi; Vincenzo Montinaro; Ernesto Paoletti; Marcello Persico; Francesco Perticone; Salvatore Petta; Massimo Puoti; Giovanni Raimondo; Maria Rendina; Anna Linda Zignego Journal: Intern Emerg Med Date: 2018-09-25 Impact factor: 3.397
Authors: Elise J Smolders; Clara T M M de Kanter; Bart van Hoek; Joop E Arends; Joost P H Drenth; David M Burger Journal: Drug Saf Date: 2016-07 Impact factor: 5.606